A Phase I study of MAGE-A1-specific TCR-transduced T cells in patients with relapsed/refractory multiple myeloma - MAGE-A1-TCR
Latest Information Update: 03 Feb 2020
At a glance
- Drugs MAGEA1 TCR (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms MAGE-A1-TCR
- 09 May 2018 According to Medigene media release, this trial is expected to start in 2018.
- 06 Sep 2017 Trial design presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.
- 03 Aug 2017 According to Medigene media release, the company expects Clinical trial authorization and initiation in 2017.